Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 306

1.

Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.

Harrison BT, Fowler E, Krings G, Chen YY, Bean GR, Vincent-Salomon A, Fuhrmann L, Barnick SE, Chen B, Hosfield EM, Hornick JL, Schnitt SJ.

Am J Surg Pathol. 2019 Sep 6. doi: 10.1097/PAS.0000000000001366. [Epub ahead of print]

PMID:
31498178
2.

Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.

Laws A, Hughes ME, Hu J, Barry WT, Dominici L, Nakhlis F, Barbie T, Duggan M, Weiss A, Rhei E, Carter K, Nimbkar S, Schnitt SJ, King TA.

Ann Surg Oncol. 2019 Nov;26(12):3846-3855. doi: 10.1245/s10434-019-07515-4. Epub 2019 Jun 20.

PMID:
31222687
3.

Evaluation of Breast and Axillary Lymph Node Specimens in Breast Cancer Patients Treated With Neoadjuvant Systemic Therapy.

Baker GM, King TA, Schnitt SJ.

Adv Anat Pathol. 2019 Jul;26(4):221-234. doi: 10.1097/PAP.0000000000000237.

PMID:
31149907
4.

Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ.

Harrison BT, Hwang ES, Partridge AH, Thompson AM, Schnitt SJ.

Mod Pathol. 2019 Sep;32(9):1257-1262. doi: 10.1038/s41379-019-0262-4. Epub 2019 Apr 12.

PMID:
30980039
5.

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.

Kensler KH, Regan MM, Heng YJ, Baker GM, Pyle ME, Schnitt SJ, Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi RM.

Breast Cancer Res. 2019 Feb 22;21(1):30. doi: 10.1186/s13058-019-1118-z.

6.

Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS).

Punglia RS, Bifolck K, Golshan M, Lehman C, Collins L, Polyak K, Mittendorf E, Garber J, Hwang SE, Schnitt SJ, Partridge AH, King TA.

JNCI Cancer Spectr. 2018 Nov;2(4):pky063. doi: 10.1093/jncics/pky063. Epub 2018 Dec 27.

7.

Problematic issues in breast core needle biopsies.

Schnitt SJ.

Mod Pathol. 2019 Jan;32(Suppl 1):71-76. doi: 10.1038/s41379-018-0137-0. Epub 2019 Jan 2. Review.

PMID:
30600318
8.

Histopathologic findings in breast surgical specimens from patients undergoing female-to-male gender reassignment surgery.

Torous VF, Schnitt SJ.

Mod Pathol. 2019 Mar;32(3):346-353. doi: 10.1038/s41379-018-0117-4. Epub 2018 Oct 11.

PMID:
30310177
9.

Androgen receptor expression in normal breast tissue and subsequent breast cancer risk.

Kensler KH, Beca F, Baker GM, Heng YJ, Beck AH, Schnitt SJ, Hazra A, Rosner BA, Eliassen AH, Hankinson SE, Brown M, Tamimi RM.

NPJ Breast Cancer. 2018 Sep 21;4:33. doi: 10.1038/s41523-018-0085-3. eCollection 2018.

10.

Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay.

Desai NV, Torous V, Parker J, Auman JT, Rosson GB, Cruz C, Perou CM, Schnitt SJ, Tung N.

Breast Cancer Res. 2018 Jul 11;20(1):75. doi: 10.1186/s13058-018-1005-z.

11.

Feasibility of analyzing DNA copy number variation in breast cancer tumor specimens from 1950 to 2010: how old is too old?

Krieger N, Nabavi S, Waterman PD, Achacoso NS, Acton L, Schnitt SJ, Habel LA.

Cancer Causes Control. 2018 Mar;29(3):305-314. doi: 10.1007/s10552-018-1006-3. Epub 2018 Feb 9.

12.

Genotype-Phenotype Correlations in Breast Cancer.

Marotti JD, Schnitt SJ.

Surg Pathol Clin. 2018 Mar;11(1):199-211. doi: 10.1016/j.path.2017.09.008. Epub 2017 Dec 15. Review.

PMID:
29413657
13.

Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.

Punglia RS, Jiang W, Lipsitz SR, Hughes ME, Schnitt SJ, Hassett MJ, Nekhlyudov L, Achacoso N, Edge S, Javid SH, Niland JC, Theriault RL, Wong YN, Habel LA.

Breast Cancer Res Treat. 2018 Feb;167(3):751-759. doi: 10.1007/s10549-017-4553-5. Epub 2017 Oct 28.

PMID:
29079937
14.

Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue.

Oh H, Eliassen AH, Beck AH, Rosner B, Schnitt SJ, Collins LC, Connolly JL, Montaser-Kouhsari L, Willett WC, Tamimi RM.

NPJ Breast Cancer. 2017 Oct 2;3:39. doi: 10.1038/s41523-017-0041-7. eCollection 2017.

15.

Reply to Rosen.

Reis-Filho JS, Geyer FC, Weigelt B, Rakha EA, Ellis IO, Schnitt SJ.

Mod Pathol. 2017 Oct;30(10):1505-1506. doi: 10.1038/modpathol.2017.70. No abstract available.

16.

Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.

Healey MA, Hirko KA, Beck AH, Collins LC, Schnitt SJ, Eliassen AH, Holmes MD, Tamimi RM, Hazra A.

Breast Cancer Res Treat. 2017 Nov;166(2):613-622. doi: 10.1007/s10549-017-4421-3. Epub 2017 Aug 8.

PMID:
28791482
17.

The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.

Geyer FC, Pareja F, Weigelt B, Rakha E, Ellis IO, Schnitt SJ, Reis-Filho JS.

Am J Pathol. 2017 Oct;187(10):2139-2151. doi: 10.1016/j.ajpath.2017.03.016. Epub 2017 Jul 20. Review.

18.

Nanoscale imaging of clinical specimens using pathology-optimized expansion microscopy.

Zhao Y, Bucur O, Irshad H, Chen F, Weins A, Stancu AL, Oh EY, DiStasio M, Torous V, Glass B, Stillman IE, Schnitt SJ, Beck AH, Boyden ES.

Nat Biotechnol. 2017 Aug;35(8):757-764. doi: 10.1038/nbt.3892. Epub 2017 Jul 17.

19.

Vascular lesions of the breast.

Baker GM, Schnitt SJ.

Semin Diagn Pathol. 2017 Sep;34(5):410-419. doi: 10.1053/j.semdp.2017.05.013. Epub 2017 May 30. Review.

PMID:
28676174
20.

Evaluation of margins in invasive carcinoma and ductal carcinoma in situ: The pathologist's perspective.

Schnitt SJ.

Breast. 2017 Aug;34 Suppl 1:S58-S60. doi: 10.1016/j.breast.2017.06.029. Epub 2017 Jun 26. No abstract available.

21.

Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma.

Schnitt SJ, Morrow M, Tung NM.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx036. No abstract available.

PMID:
28376199
22.

EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses' Health Studies.

Beca F, Kensler K, Glass B, Schnitt SJ, Tamimi RM, Beck AH.

Breast Cancer Res. 2017 Mar 2;19(1):21. doi: 10.1186/s13058-017-0817-6.

23.

Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer.

Oh H, Eliassen AH, Wang M, Smith-Warner SA, Beck AH, Schnitt SJ, Collins LC, Connolly JL, Montaser-Kouhsari L, Polyak K, Tamimi RM.

NPJ Breast Cancer. 2016;2. pii: 16032. doi: 10.1038/npjbcancer.2016.32. Epub 2016 Oct 26.

24.

Benign breast lesions that mimic malignancy.

Torous VF, Schnitt SJ, Collins LC.

Pathology. 2017 Feb;49(2):181-196. doi: 10.1016/j.pathol.2016.12.002. Epub 2017 Jan 6.

PMID:
28069257
25.

Current topics in breast pathology: expert perspectives.

Dahlstrom JE, Rakha EA, Lakhani SR, Schnitt SJ.

Pathology. 2017 Feb;49(2):109-110. doi: 10.1016/j.pathol.2016.12.001. Epub 2017 Jan 6. No abstract available.

PMID:
28069256
26.

IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity.

Chiang S, Weigelt B, Wen HC, Pareja F, Raghavendra A, Martelotto LG, Burke KA, Basili T, Li A, Geyer FC, Piscuoglio S, Ng CK, Jungbluth AA, Balss J, Pusch S, Baker GM, Cole KS, von Deimling A, Batten JM, Marotti JD, Soh HC, McCalip BL, Serrano J, Lim RS, Siziopikou KP, Lu S, Liu X, Hammour T, Brogi E, Snuderl M, Iafrate AJ, Reis-Filho JS, Schnitt SJ.

Cancer Res. 2016 Dec 15;76(24):7118-7129. Epub 2016 Oct 20.

27.

Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family.

Geyer FC, Berman SH, Marchiò C, Burke KA, Guerini-Rocco E, Piscuoglio S, Ng CK, Pareja F, Wen HY, Hodi Z, Schnitt SJ, Rakha EA, Ellis IO, Norton L, Weigelt B, Reis-Filho JS.

Mod Pathol. 2017 Jan;30(1):69-84. doi: 10.1038/modpathol.2016.161. Epub 2016 Oct 7.

28.

A prospective study of endometriosis and risk of benign breast disease.

Farland LV, Tamimi RM, Eliassen AH, Spiegelman D, Collins LC, Schnitt SJ, Missmer SA.

Breast Cancer Res Treat. 2016 Oct;159(3):545-52. doi: 10.1007/s10549-016-3957-y. Epub 2016 Sep 7.

29.

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ.

Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):287-295. doi: 10.1016/j.prro.2016.06.011. Epub 2016 Jun 24.

30.

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ.

Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS.

J Clin Oncol. 2016 Nov 20;34(33):4040-4046. doi: 10.1200/JCO.2016.68.3573. Epub 2016 Oct 31.

31.

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ.

Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS.

Ann Surg Oncol. 2016 Nov;23(12):3801-3810. Epub 2016 Aug 15. Review.

32.

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.

Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, O'Toole SA, Viale G, Van de Vijver K, de Wind R, von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R.

Mod Pathol. 2016 Oct;29(10):1155-64. doi: 10.1038/modpathol.2016.109. Epub 2016 Jul 1.

33.

Reply to breast cancer risk by the extent and type of atypical hyperplasia.

Collins LC, Schnitt SJ, Tamimi RM.

Cancer. 2016 Oct;122(19):3088-9. doi: 10.1002/cncr.30149. Epub 2016 Jun 28. No abstract available.

34.

In Reply.

Schnitt SJ, Morrow M.

Arch Pathol Lab Med. 2016 Feb;140(2):116. doi: 10.5858/arpa.2015-0355-LE. No abstract available.

PMID:
26910213
35.

Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.

Tung N, Garber JE, Hacker MR, Torous V, Freeman GJ, Poles E, Rodig S, Alexander B, Lee L, Collins LC, Schnitt SJ.

NPJ Breast Cancer. 2016 Feb 24;2:16002. doi: 10.1038/npjbcancer.2016.2. eCollection 2016.

36.

Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.

Hassett MJ, Jiang W, Habel LA, Nekhlyudov L, Achacoso N, Acton L, Schnitt SJ, Schrag D, Punglia RS.

Breast Cancer Res Treat. 2016 Feb;155(3):541-9. doi: 10.1007/s10549-016-3692-4. Epub 2016 Feb 3.

37.

Analyzing historical trends in breast cancer biomarker expression: a feasibility study (1947-2009).

Krieger N, Habel LA, Waterman PD, Shabani M, Ellison-Loschmann L, Achacoso NS, Acton L, Schnitt SJ.

NPJ Breast Cancer. 2015;1. pii: 15016. Epub 2015 Oct 7.

38.

Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.

Guerini-Rocco E, Piscuoglio S, Ng CK, Geyer FC, De Filippo MR, Eberle CA, Akram M, Fusco N, Ichihara S, Sakr RA, Yatabe Y, Vincent-Salomon A, Rakha EA, Ellis IO, Wen YH, Weigelt B, Schnitt SJ, Reis-Filho JS.

J Pathol. 2016 Apr;238(5):677-88. doi: 10.1002/path.4691.

39.

E-cadherin immunohistochemistry in breast pathology: uses and pitfalls.

Canas-Marques R, Schnitt SJ.

Histopathology. 2016 Jan;68(1):57-69. doi: 10.1111/his.12869. Review.

PMID:
26768029
40.

Phyllodes tumours of the breast: a consensus review.

Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, Calvo JP, Dabbs DJ, Ellis IO, Eusebi V, Farshid G, Fox SB, Ichihara S, Lakhani SR, Rakha EA, Reis-Filho JS, Richardson AL, Sahin A, Schmitt FC, Schnitt SJ, Siziopikou KP, Soares FA, Tse GM, Vincent-Salomon A, Tan PH.

Histopathology. 2016 Jan;68(1):5-21. doi: 10.1111/his.12876. Review.

41.

Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies.

Collins LC, Aroner SA, Connolly JL, Colditz GA, Schnitt SJ, Tamimi RM.

Cancer. 2016 Feb 15;122(4):515-20. doi: 10.1002/cncr.29775. Epub 2015 Nov 13.

42.

Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020).

Nakhlis F, Gilmore L, Gelman R, Bedrosian I, Ludwig K, Hwang ES, Willey S, Hudis C, Iglehart JD, Lawler E, Ryabin NY, Golshan M, Schnitt SJ, King TA.

Ann Surg Oncol. 2016 Mar;23(3):722-8. doi: 10.1245/s10434-015-4922-4. Epub 2015 Nov 5.

43.

Recurrence of breast carcinoma as Paget disease of the skin at a prior core needle biopsy site: Case report and review of the literature.

Calvillo KZ, Guo L, Brostrom V, Schnitt SJ, Hong X, Raza S, Lester SC.

Int J Surg Case Rep. 2015;15:152-6. doi: 10.1016/j.ijscr.2015.08.041. Epub 2015 Sep 9.

44.

Postmenopausal mammographic breast density and subsequent breast cancer risk according to selected tissue markers.

Yaghjyan L, Pettersson A, Colditz GA, Collins LC, Schnitt SJ, Beck AH, Rosner B, Vachon C, Tamimi RM.

Br J Cancer. 2015 Sep 29;113(7):1104-13. doi: 10.1038/bjc.2015.315. Epub 2015 Sep 3.

45.

Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study.

Collins LC, Achacoso N, Haque R, Nekhlyudov L, Quesenberry CP Jr, Schnitt SJ, Habel LA, Fletcher SW.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S502-8. doi: 10.1245/s10434-015-4641-x. Epub 2015 Jun 10.

PMID:
26059650
46.

Diagnostic concordance among pathologists interpreting breast biopsy specimens.

Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson AN, Nelson HD, Pepe MS, Allison KH, Schnitt SJ, O'Malley FP, Weaver DL.

JAMA. 2015 Mar 17;313(11):1122-32. doi: 10.1001/jama.2015.1405.

47.

Current management of lesions associated with an increased risk of breast cancer.

Morrow M, Schnitt SJ, Norton L.

Nat Rev Clin Oncol. 2015 Apr;12(4):227-38. doi: 10.1038/nrclinonc.2015.8. Epub 2015 Jan 27. Review.

PMID:
25622978
48.

Computational pathology to discriminate benign from malignant intraductal proliferations of the breast.

Dong F, Irshad H, Oh EY, Lerwill MF, Brachtel EF, Jones NC, Knoblauch NW, Montaser-Kouhsari L, Johnson NB, Rao LK, Faulkner-Jones B, Wilbur DC, Schnitt SJ, Beck AH.

PLoS One. 2014 Dec 9;9(12):e114885. doi: 10.1371/journal.pone.0114885. eCollection 2014.

49.

Intakes of fat and micronutrients between ages 13 and 18 years and the incidence of proliferative benign breast disease.

Su X, Boeke CE, Collins LC, Baer HJ, Willett WC, Schnitt SJ, Connolly JL, Rosner B, Colditz GA, Tamimi RM.

Cancer Causes Control. 2015 Jan;26(1):79-90. doi: 10.1007/s10552-014-0484-1. Epub 2014 Nov 7.

50.

Does isolated flat epithelial atypia on vacuum-assisted breast core biopsy require surgical excision?

Dialani V, Venkataraman S, Frieling G, Schnitt SJ, Mehta TS.

Breast J. 2014 Nov-Dec;20(6):606-14. doi: 10.1111/tbj.12332. Epub 2014 Sep 27.

PMID:
25264188

Supplemental Content

Loading ...
Support Center